Treatment of anemia in non-myeloid malignancies where anemia is due to effect of chemotherapy & in Zidovudine-treated HIV-infected patients. Reduction of allogeneic blood transfusion in surgery patients.
SCAdult: Cancer patient on chemotherapy 150-300 IU/kg 3 times wkly or 40,000 IU once wkly. Zidovudine-treated HIV-infected patient Determine endogenous serum erythropoietin level prior to transfusion. Surgery patient 300 IU/kg/day for 10 days before surgery, on the day of surgery & 4 days after surgery. Alternate dose schedule: 600 IU/kg once wkly (21, 14 & 7 days before surgery) plus a 4th dose on the day of surgery.
Increased mortality in patients w/ target hematocrit of 42%. Control BP before initiation of therapy. Chronic renal failure patients w/ uncontrolled HTN; seizures. Underlying hematologic disease; patients w/ history of seizure disorder or underlying hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes or hyper coagulable disorders); porphyria. Fe deficiency; underlying infectious, inflammatory or malignant processes; occult blood loss; folic acid or vit B12 deficiencies; hemolysis; Al intoxication; osteitis fibrosa cystica. May require increased anticoagulation w/ heparin to prevent clotting of the artificial kidney. Pregnancy & lactation.
Sign Out
